Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On February 3, 2025, Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 12,116 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on January 12, 2024.
• The RSUs vest annually, with 25% vesting each year beginning on February 1, 2025, contingent upon Burnett's continued service to the Issuer.
• The shares were sold at a weighted average price of $12.7, with individual transactions ranging from $12.545 to $13.0096.
• Following the transaction, Burnett beneficially owns 114,862 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock sales are a common occurrence, particularly around vesting events. This sale appears to be related to tax obligations, which is a typical reason for such transactions.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the stated reason for the sale.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Patrick Burnett, Form 4, Executive Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership